Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Xenon Pharmaceuticals (NASDAQ:XENE), maintaining a price target of $65.
April 10, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Xenon Pharmaceuticals, with a $65 price target.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald, along with a substantial price target of $65, suggests a strong vote of confidence in Xenon Pharmaceuticals. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in XENE's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100